Question 1

What is IQVIA's P/B ratio?

Accepted Answer

IQVIA (IQV) P/B ratio is 5.4× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for IQVIA?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For IQVIA specifically, the relevant sector benchmark is the current sector median of 3.2×.

Question 5

Is IQVIA's P/B ratio high or low?

Accepted Answer

IQVIA's P/B ratio of 5.4× is below its own 5-year average of 6.5× and above the sector median of 3.2×. That places the current reading at the 19th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is IQVIA's historical P/B ratio range?

Accepted Answer

In the available daily series, IQVIA (IQV) P/B ratio has ranged from a low of 2.1× in 2016 to a high of 9.5× in 2021. The 5-year average is 6.5× and the 5-year median is 6.3×.

Question 7

What was IQVIA's P/B ratio in 2025?

Accepted Answer

IQVIA (IQV) P/B ratio at the end of 2025 was 5.9×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does IQVIA's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$38.3B	$6.5B	5.9×	+0.1×	Dec 31, 2025
2024	$35.2B	$6.07B	5.8×	-1.1×	Dec 31, 2024
2023	$42.1B	$6.11B	6.9×	+0.3×	Dec 31, 2023
2022	$38B	$5.77B	6.6×	-2.3×	Dec 31, 2022
2021	$53.8B	$6.04B	8.9×	+3.2×	Dec 31, 2021
2020	$34.3B	$6B	5.7×	+0.8×	Dec 31, 2020
2019	$29.8B	$6B	5.0×	+1.5×	Dec 31, 2019
2018	$23.2B	$6.71B	3.5×	+0.9×	Dec 31, 2018
2017	$20.5B	$8.11B	2.5×	+0.4×	Dec 31, 2017
2016	$18.2B	$8.63B	2.1×	—	Dec 31, 2016
2015	$8.31B	-$564M	—	—	Dec 31, 2015
2014	$7.4B	-$704M	—	—	Dec 31, 2014
2013	$5.99B	-$667M	—	—	Dec 31, 2013
2012	$5.28B	-$1.36B	—	—	Dec 31, 2012


Charles River (CRL)	2.6×
Danaher (DHR)	2.6×
Spruce Biosciences (SPRB)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Solventum (SOLV)	2.3×
Medtronic (MDT)	2.2×
Elevance Health (ELV)	1.9×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Zimmer Biomet Holdings (ZBH)	1.4×
Revvity (RVTY)	1.4×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for IQVIA (IQV) 2016-2026

P/B Ratio daily chart for IQVIA (IQV)

Historical P/B Ratio for IQVIA (IQV) from 2012 to 2025

About P/B Ratio at IQVIA (IQV)

IQVIA P/B Ratio by Year

IQVIA P/B Ratio 2025: 5.9×

IQVIA P/B Ratio 2024: 5.8×

IQVIA P/B Ratio 2023: 6.9×

IQVIA P/B Ratio 2022: 6.6×

IQVIA P/B Ratio 2021: 8.9×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

IQVIA (IQV) Key Financials